List of Excipients in Branded Drug AZACTAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	AZACTAM	aztreonam	0003-2560	ARGININE
A-S Medication Solutions	AZACTAM	aztreonam	50090-7494	ARGININE

AZACTAM Excipient Strategy and Commercial Opportunities for Aztreonam Injection

Last updated: September 1, 2026

AZACTAM is an injectable aztreonam product whose core excipient strategy is simple: arginine supports the parenteral powder formulation, while the commercial opportunity lies in reconstitution convenience, container systems, stability, hospital workflow, and differentiated delivery formats. The original U.S. product has no meaningful remaining market exclusivity barrier for conventional generic aztreonam injection. Excipient innovation can support commercial differentiation, but it is unlikely to create broad patent protection unless linked to a new dosage form, stability profile, delivery device, or clinical use.

What is AZACTAM and which excipients does it contain?

AZACTAM is the brand name for aztreonam for injection, a monobactam antibacterial used against susceptible gram-negative organisms. It is administered by intravenous or intramuscular injection and is supplied as a sterile powder requiring reconstitution before use (U.S. Food and Drug Administration [FDA], 2023).

The principal excipient is arginine.

Product characteristic	AZACTAM position
Active ingredient	Aztreonam
Dosage form	Sterile injectable powder
Routes	Intravenous and intramuscular
Common vial strengths	500 mg, 1 g and 2 g
Principal excipient	L-arginine
Typical formulation role	Solubilization and pH control
Preservative status	Preservative-free single-dose vial
U.S. approval	1986
FDA pathway for generic competitors	ANDA
Biosimilar classification	Not applicable

The product is formulated with an acidic-to-neutral pH profile after reconstitution. The label identifies arginine as the inactive component and provides instructions for reconstitution with sterile water for injection or compatible infusion solutions. Stability varies by diluent, concentration, temperature and storage conditions (FDA, 2023).

Arginine is commercially important because it must meet parenteral quality requirements, including control of bioburden, endotoxin, particulate matter, elemental impurities and extractables. A lower-cost excipient is not automatically substitutable where it changes solution stability, pH, osmolality, reconstitution performance or impurity formation.

What excipient functions are most important in AZACTAM?

Arginine has several formulation functions, although the approved label does not position it as a therapeutic ingredient.

Solubilization

Aztreonam is supplied as a dry sterile powder. The formulation must dissolve rapidly and completely after addition of the selected diluent. Incomplete dissolution creates administration delays and raises the risk of visible or subvisible particulate matter.

pH management

Arginine contributes to the formulation environment required to maintain aztreonam in solution after reconstitution. Any replacement with phosphate, citrate, acetate or another buffer would require comparative assessment of pH, degradation products, osmolality and compatibility.

Reconstitution performance

Hospital users value rapid dissolution, low foaming, low withdrawal loss and predictable final concentration. These attributes can be improved through powder morphology, fill weight control, vial geometry and stopper design, even when the qualitative excipient composition remains unchanged.

Parenteral safety

A conventional AZACTAM-style product is expected to remain preservative-free. The use of preservatives could introduce compatibility, toxicity and regulatory problems, particularly for intravenous administration. A supplier strategy should prioritize compendial-grade L-arginine with low endotoxin and low particulate burden rather than pursue marginal cost savings through a nonstandard excipient.

What formulations are protected by AZACTAM-related intellectual property?

The original AZACTAM formulation is unlikely to provide a substantial standalone patent barrier to generic aztreonam injection. AZACTAM was approved in the 1980s, and conventional aztreonam injection has been subject to ANDA competition for many years.

Protection category	Commercial assessment
Basic aztreonam composition	Expired or commercially obsolete
Original arginine-containing injectable formulation	Limited barrier to generic entry
Conventional vial presentation	Weak patent differentiation
Reconstitution instructions	Generally not a durable exclusivity asset
New ready-to-use formulation	Potential 505(b)(2) or formulation patent opportunity
New delivery device	Potential device and combination-product protection
Method-of-use claims	Possible only for differentiated clinical use
Manufacturing process	Potential trade-secret and process-patent value

The FDA Orange Book remains the controlling source for listed patents and regulatory exclusivity associated with an approved drug application. The AZACTAM listing and long commercial history do not indicate a current composition-of-matter or formulation barrier that would prevent conventional generic entry (FDA, 2024a).

Patent value is more likely to arise from a new product architecture than from the basic use of arginine. Potentially protectable features include:

• A stable ready-to-use aztreonam solution.
• A dual-chamber vial separating aztreonam from the diluent until administration.
• A prefilled syringe with validated stability.
• A high-concentration formulation that reduces infusion volume.
• A novel container closure system that limits moisture ingress.
• A specific lyophilized cake structure that improves reconstitution time.
• A formulation with defined impurity limits during extended storage.
• A device-enabled administration method for outpatient or home infusion.

A patent directed only to “aztreonam plus arginine” would face substantial validity and obviousness risk because the combination is associated with the established product. A stronger claim set would combine composition, stability, packaging and administration limitations.

When does AZACTAM lose exclusivity?

AZACTAM lost practical U.S. market exclusivity years ago. The product was approved in 1986, and its original regulatory and patent protections do not block generic aztreonam injection today.

Milestone	Date or status
Original U.S. approval	1986
New chemical entity exclusivity	Expired
Original formulation patent protection	Expired or commercially ineffective
ANDA competition	Established
Current conventional generic risk	High
Remaining opportunity	Differentiated formulation, packaging or delivery

The relevant commercial question is no longer whether generic entry is legally possible. It is whether a sponsor can create a product with sufficient hospital, outpatient or payer value to justify a premium over standard generic vials.

Which companies are challenging AZACTAM?

Generic aztreonam injection has been supplied by multiple manufacturers over time, including large generic companies and contract manufacturers. The competitive market is driven by FDA-approved ANDA products rather than by biosimilar competition.

FDA labeling and product databases identify generic aztreonam injection products from companies such as Teva Pharmaceuticals and other ANDA sponsors, depending on the strength, route and market period (FDA, 2024b).

The main competitive variables are:

• Supply reliability.
• Contract price.
• Vial strength availability.
• Shortage performance.
• Reconstitution time.
• Diluent compatibility.
• Hospital pharmacy handling.
• Availability for outpatient parenteral antimicrobial therapy.
• Procurement status under group purchasing organizations.

Because aztreonam is an older hospital antibiotic, supply continuity can be more valuable than marginal formulation novelty. A manufacturer that can maintain dependable supply during beta-lactam shortages may win contracts without changing the active ingredient or excipient system.

What is the FDA regulatory status of AZACTAM and generic aztreonam?

AZACTAM is an approved small-molecule drug, not a biologic. A conventional generic product generally follows the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.

For an injectable solution or powder for injection, the regulatory burden focuses on:

• Active ingredient identity and strength.
• Sterility and endotoxin control.
• Particulate matter.
• Container-closure integrity.
• Reconstitution and dissolution.
• pH and osmolality.
• Stability and degradation products.
• Extractables and leachables.
• Diluent compatibility.
• Labeling and administration instructions.

A materially different formulation may require a 505(b)(2) application instead of an ANDA. This pathway can support new excipients, new concentrations, new delivery devices or new administration methods, but it also creates a higher clinical and regulatory burden than a conventional generic.

The use of a novel excipient in an injectable product is commercially difficult because FDA’s inactive ingredient database does not eliminate the need to establish product-specific safety and manufacturing control. Parenteral precedent helps, but it does not guarantee approval for a new concentration, route or exposure level (FDA, 2024c).

How strong is the AZACTAM patent estate?

The conventional AZACTAM patent estate is weak as a barrier to generic injection. Its strength is higher for commercial know-how than for blocking intellectual property.

IP asset	Relative strength	Reason
Original aztreonam molecule	Low	Historical protection has expired
Arginine-containing powder	Low	Closely associated with the established product
Standard vial presentation	Low	Easy to design around
Sterile manufacturing process	Medium	Valuable as know-how; patent enforceability varies
Stability-controlled formulation	Medium to high	Stronger if supported by unexpected data
Dual-chamber delivery system	Medium to high	Device and formulation claims can be combined
Ready-to-use aztreonam	High commercial potential	Could reduce hospital preparation burden
Inhaled aztreonam platform	Separate estate	Different product and clinical positioning

A new patent portfolio should include composition claims, process claims, container claims and use claims. The commercial objective should be to create multiple enforcement points rather than rely on a single excipient claim.

What formulation opportunities exist for aztreonam?

Ready-to-use intravenous bags

A ready-to-use aztreonam infusion could eliminate pharmacy reconstitution and reduce preparation errors. The principal technical barriers are solution stability, degradation during refrigerated storage, container compatibility and acceptable shelf life.

A successful product could compete for hospital formulary preference and outpatient infusion use. The formulation would need a commercially useful shelf life, preferably measured in months rather than days, under standard distribution conditions.

Dual-chamber vials

A dual-chamber vial could separate the aztreonam powder from sterile diluent until activation. This approach preserves the powder’s stability while reducing preparation steps. It could be more practical than a ready-to-use solution if aztreonam shows limited long-term solution stability.

The patent opportunity would extend beyond the excipient blend to the chamber geometry, activation mechanism, stopper configuration and validated reconstitution sequence.

Prefilled syringes

A prefilled syringe could support emergency departments, ambulatory care and home infusion. The main challenges are syringe-material compatibility, adsorption, particulate control, needle-system compatibility and stability at the selected concentration.

Concentrated formulations

A concentrated product could reduce infusion volume and storage requirements. It would need careful evaluation of local tolerability for intramuscular use, infusion-site reactions, osmolality and dilution behavior.

Pediatric and renal-dose presentations

Aztreonam dosing varies with renal function and patient characteristics. Smaller vial sizes or dose-flexible presentations could reduce waste. The commercial value would be operational rather than patent-driven unless the presentation is paired with a protected device or administration method.

How does AZACTAM compare with CAYSTON?

CAYSTON contains aztreonam lysine and is an inhaled product for a different clinical setting. It should not be treated as a direct formulation equivalent to AZACTAM.

Attribute	AZACTAM	CAYSTON
Active ingredient	Aztreonam	Aztreonam lysine
Route	IV or IM	Inhalation
Primary setting	Systemic antibacterial treatment	Inhaled treatment for cystic fibrosis patients with Pseudomonas aeruginosa
Form	Injectable powder	Inhalation solution and nebulizer system
Excipient strategy	Arginine-based parenteral powder	Inhalation-specific formulation and device
Regulatory product class	Small-molecule injectable	Small-molecule inhaled combination
Generic substitution	Conventional injection generics	Requires route, device and clinical equivalence

The inhaled market has a different value proposition. An AZACTAM-derived inhalation product would need to address aerosol performance, lung deposition, device compatibility and local tolerability. It would not be a simple excipient reformulation of the injectable product.

What manufacturing and IP barriers affect excipient commercialization?

The highest-value manufacturing barriers are process controls rather than the identity of the excipient.

Key controls include:

1. L-arginine source qualification and supply redundancy.
2. Low-endotoxin handling from receipt through sterile filling.
3. Moisture control during powder processing.
4. Uniform fill-weight distribution.
5. Control of cake appearance and reconstitution time.
6. Container-closure integrity.
7. Compatibility with elastomeric stoppers and vial coatings.
8. Stability-indicating analytical methods.
9. Control of aztreonam degradation products.
10. Validated sterilization or aseptic processing.

A supplier can create defensible value by offering pharmaceutical-grade arginine with documented batch consistency, low particulate levels, qualified global manufacturing sites and regulatory support. The excipient itself may remain unpatented, but the supplier relationship can be protected through qualification costs, technical know-how and dual-source switching barriers.

What generic launch risks exist for an AZACTAM reformulation?

A conventional generic launch faces price erosion and contract competition. A differentiated product faces different risks.

Launch scenario	Commercial upside	Primary risk
Standard generic vial	Low to medium	Rapid price erosion
Premium vial with faster reconstitution	Medium	Weak willingness to pay
Dual-chamber vial	Medium to high	Device cost and regulatory complexity
Ready-to-use bag	High	Solution stability and distribution shelf life
Prefilled syringe	Medium	Container and device compatibility
Inhaled reformulation	High	Separate clinical and device development
Home-infusion presentation	Medium to high	Payer and channel adoption

Paragraph IV litigation is unlikely to be the central issue for ordinary aztreonam injection because the original product’s practical exclusivity has expired and generic competition is established. Litigation risk would become more relevant if a new sponsor obtained formulation, device or method-of-use patents and sought to list them in the Orange Book. A Paragraph IV challenge could then target the listed patents, while non-listed manufacturing and trade-secret rights would remain outside the ordinary Orange Book framework (FDA, 2024a).

What licensing deals could support AZACTAM commercial expansion?

The most relevant licensing targets are not basic aztreonam rights. They are enabling technologies.

Potential deal structures include:

• Licensing a dual-chamber vial platform from a device company.
• Acquiring a ready-to-use beta-lactam stability platform.
• Partnering with a sterile injectable contract development and manufacturing organization.
• Licensing a home-infusion pump or prefilled syringe system.
• Acquiring regional rights to an approved aztreonam ANDA.
• Forming a supply agreement for qualified low-endotoxin L-arginine.
• Licensing inhalation technology separate from AZACTAM injection.

A conventional excipient supplier would usually capture more value through a long-term supply and technical-services agreement than through a royalty-bearing patent license. A formulation owner with clinical differentiation could justify milestone, royalty and territory-based licensing terms.

What is the commercial outlook for AZACTAM excipients?

The largest near-term opportunity is a reliable, low-cost arginine-based injectable platform for generic supply. The larger strategic opportunity is a differentiated presentation that reduces hospital preparation work.

Commercial attractiveness ranks as follows:

1. Dual-chamber vial with established powder stability.
2. Ready-to-use infusion product with extended refrigerated shelf life.
3. Prefilled syringe for outpatient or emergency use.
4. Smaller-dose vials to reduce waste.
5. Standard arginine-based generic injection.
6. New inhaled product based on aztreonam lysine.

No public standalone revenue line for AZACTAM or its arginine excipient component establishes a reliable brand-level revenue estimate. Revenue exposure should therefore be modeled from hospital injectable market share, vial volume, contract price, shortage premiums and adoption of differentiated presentations rather than from historical AZACTAM brand sales.

Key Takeaways

• AZACTAM is an arginine-containing sterile aztreonam powder for IV and IM administration.
• The original product has no practical exclusivity barrier blocking conventional generic entry.
• Arginine is the central excipient opportunity, but simple substitution is unlikely to create strong IP.
• The strongest commercial opportunities involve ready-to-use bags, dual-chamber vials and prefilled syringes.
• A 505(b)(2) strategy may be appropriate for materially different formulations or delivery systems.
• Conventional ANDA products will face substantial price and procurement pressure.
• CAYSTON is a separate inhaled aztreonam lysine product and should not be treated as an AZACTAM formulation equivalent.
• Manufacturing reliability, low-endotoxin excipient supply and container compatibility may create more commercial value than a narrow excipient patent.
• New IP should combine formulation, stability, packaging, device and administration claims.
• Biosimilar competition does not apply because aztreonam is a small-molecule antibiotic.

FAQs About AZACTAM Excipient and Commercial Strategy

Is arginine essential to every generic aztreonam injection?

No. A generic sponsor must meet applicable pharmaceutical equivalence and performance requirements, but the formulation must be demonstrated to provide appropriate stability, sterility, reconstitution and product quality.

Can a new arginine grade obtain FDA exclusivity?

An excipient grade alone generally does not create drug exclusivity. Commercial protection would more likely come from a novel formulation, manufacturing process, stability profile or delivery system.

Can AZACTAM be converted into a ready-to-use infusion?

Potentially, but the product would require extensive stability, compatibility, container-closure and regulatory development. A ready-to-use product could fall outside the scope of a conventional ANDA if its formulation or presentation is materially different.

Does AZACTAM have biosimilar risk?

No. Biosimilar regulation applies to biological products. Aztreonam is a chemically synthesized small molecule, so competitive risk comes from generic ANDA products and differentiated reformulations.

Which excipient is most commercially attractive for aztreonam?

L-arginine remains the most directly relevant excipient for the established injectable powder. The higher-value opportunity is not a new excipient identity but a controlled arginine-based formulation paired with improved packaging, reconstitution or administration.

References

1. U.S. Food and Drug Administration. (2023). AZACTAM (aztreonam for injection, USP) prescribing information. Bristol-Myers Squibb Company.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024c). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm